Pershing Square, Pharma Join To Buy Botox Maker

Apr 22 2014 | 2:03pm ET

For its latest activist effort, Pershing Square Capital Management has already enlisted a buyer.

The New York-based hedge fund and Valeant Pharmaceuticals have joined forces in a hostile bid for Allergan Inc., the pharmaceutical company that makes Botox. Since striking its agreement with Valeant, Pershing Square has bought up some 9.7% of Allergan’s shares.

The deal, for cash and Valeant stock, is worth in excess of $45 billion.

Valeant has been seeking a deal for Allergan for a year, to no avail. The company said the merger would “create an unrivaled platform for growth and value creation in healthcare.”


In Depth

Kettera Q&A: The Advantages of Alternative Investment Platforms

Oct 28 2016 | 5:52pm ET

The past several years have seen a distinct push towards easier and cheaper access...

Lifestyle

Midtown's Plaza District Fades As Manhattan Office Landscape Shifts

Nov 22 2016 | 6:32pm ET

Lower leasing costs, more efficient office space and the hope of projecting an image...

Guest Contributor

Nowhere to Hide: Why the Future of Asset Management Depends on Innovation

Nov 15 2016 | 6:55pm ET

Information technology has reshaped the asset management industry’s periphery,...

 

From the current issue of

Chicago-based independent futures brokerage and clearing firm R.J. O’Brien & Associates (RJO) has hired industry veteran Daniel Staniford as Executive Director, responsible for the firm’s institutional business development in New York and London.

AVAILABLE NOW at BARNES & NOBLE

NEWSTAND LOCATOR